Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schieffer, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schieffer, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Interaction of interleukin-6 and angiotensin II in atherosclerosis: culprit for inflammation?

B. Schieffer*

Abteilung Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany

* Bernhard Schieffer, MD, Abteilung Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany
schiefferbernhard{at}mh.hannover

Abstract

Atherosclerosis is a chronic inflammatory disease perpetuated by a variety of pro-inflammatory mediators. Fatal outcomes of this disease, which include myocardial infarction, stroke, and sudden death, remain the major cause of morbidity and mortality in industrialized countries. Accumulated evidence obtained from pathological observations, state-of-the-art imaging, and large-scale clinical trials showed that these fatal events are mainly the results of pathological vascular remodeling processes, suggesting a close interaction between inflammation, vascular remodeling, and the renin-angiotensin system. The Heart Outcomes and Prevention Evaluation (HOPE) study demonstrated that the renin-angiotensin system blockade reduces fatal and nonfatal clinical ischaemic events in high-risk patients, which further implicate the renin-angiotensin system in plaque development and stability. Since experimental and clinical evidence point to inflammatory mediators such as interferon-{gamma}, interleukin-1ß, interleukin-18, and interleukin-10 as well as interleukin-6 as promoters/predictors of cardiovascular events, this paper discusses the clinical basis and the potential molecular and cellular interactions between the RAS and cytokines and their potential impact on remodeling processes at the atherosclerotic plaques.

Key Words: angiotensin II • interleukin-6 • matrix metalloproteinases • C-reactive protein • atherosclerosis • renin-angiotensin system (RAS)

References

  1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153[Abstract/Free Full Text]
  2. Ross R. Pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809[CrossRef][Medline]
  3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115–126[Free Full Text]
  4. Van der Waal AC, Becker AE, Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:34–44
  5. Libby P. Molecular bases of the acute coronary syndrome. Circulation. 1995;21:2844–2850
  6. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J. 1985;53:363–373[Free Full Text]
  7. Aldermann MH, Madhavan S, Ooi WL, Cohen H, Sealy JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098–1104[Abstract]
  8. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641–644[CrossRef][Medline]
  9. Cambien F, Costerousse O, Tirret L, et al. Plasma levels and gene polymorphism of angiotensin converting enzyme in relation to myocardial infarction. Circulation. 1994;90:669–676[Abstract/Free Full Text]
  10. Rigart B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–1346
  11. Alexander RW. Inflammation and Coronary Artery Disease. N Engl J Med. 1994;331(7):468–469[Free Full Text]
  12. Hernandez-Presa M, Bustos C, Ortega M, et al. Angiotensinn-converting enzyme inhibition prevents arterial nuclear factor-{kappa}B activation, monocyte chemoattractant protein-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532–1541[Abstract/Free Full Text]
  13. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586–1589[Abstract/Free Full Text]
  14. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation. 2001;23(103):448–454
  15. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation. 1997;96:3264–3265
  16. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–1148[Abstract/Free Full Text]
  17. Han Y, Runge M, Brasier A. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-{kappa}B transcription factor. Circ Res. 1999;84:695–703[Abstract/Free Full Text]
  18. Schieffer B, Kowert A, Brauer N, et al. Irbesartan inhibits angiotensin II-induced pro-inflammatory and prothrombotic factors in human coronary arteries: role of the JAK/STAT cascade. Eur Heart J. 1998;(Suppl. II):322
  19. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci. 1997. p. 14483–14488
  20. Northermann W, Braciak TA, Hattori M, Lee F, Fey GH. Structure of the rat IL-6 gene and its expression in macrophage-derived cells. J Biol Chem. 1989;264:16072–16082[Abstract/Free Full Text]
  21. Kishimoto T, Akira S, Narazaki M, Taga T. IL-6 family of cytokines and gp130. Blood. 1995;86:1243–1254[Free Full Text]
  22. Chakraborti S, Chakraborti T. Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: a brief overview. Cell Signal. 1998;10(10):675–683[CrossRef][Web of Science][Medline]
  23. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655[Abstract/Free Full Text]
  24. Fuhrman B, Oiknine J, Aviram M. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL and affect their secretory properties. Atherosclerosis. 1994;111:65–78[CrossRef][Web of Science][Medline]
  25. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E deficient mice. Biochem Biophys Res Commun. 1997;236:622–625[CrossRef][Web of Science][Medline]
  26. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiartherogenic effect of captopril in Watanabe heritable hyperlipidemic rabbits. Hypertension. 1990;15:327–331[Abstract/Free Full Text]
  27. Hayek T, Keidar S, Mei-Yi, Oikine J, Breslow J. Effect of angiotensin converting enzyme inhibitors on LDL lipid peroxidation and atherosclerosis progression in apoE-deficient mice. Circulation. 1995;92(Suppl 1):I–625
  28. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15:S65–S72[CrossRef]
  29. Ridker PM, Gaboury CJL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87:1969–1973[Abstract/Free Full Text]
  30. Ridker PM, Vaughan DE. Hemostatic factors and the risk of myocardial infarction. N Engl J Med. 1995;333:389–390[Free Full Text]
  31. Pfeffer M, Braunwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669–677[Abstract]
  32. The SOLVD Investigators. Effect of enllapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med. 1992;327:568–574[Web of Science][Medline]
  33. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40-ligand signaling in atherosclerosis. Proc Natl Acad Sci. 1997. p. 1931–1936 5
  34. Fiotti N, Giansante C, Ponte E, et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis. 1999;145(1):51–60[CrossRef][Web of Science][Medline]
  35. Rabbani R, Topol EJ. Strategies to achieve coronary artery plaque stabilization. Cardiovasc Res. 1999;41:401–417
  36. Kalra D, Sivusabvasubramanian N, Mann DL. Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation. 2002;105:2198–2205[Abstract/Free Full Text]
  37. Biassuci L, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874–877[Abstract/Free Full Text]
  38. Marx N, Neumann FJ, Ott I, et al. Induction of cytokine expression in leucocytes in acute myocardial infarction. J Am Coll Cardiol. 1997;30:165–170[Abstract]
  39. Solis-Herruzo JA, Rippe A, Schrum LW, et al. Interleukin 6 increases ra metalloproteinases-13 gene expression through stimulation of activator protein 1 transcription factor in cultured fibroblasts. J Biol Chem. 1996;274:30919–30926
  40. Rekhter MD, Hicks GW, Brammer DW, et al. Hypercholesterolemia causes mechanical weakening of rabbit atheroma: local collagen loss as a prerequisite of plaque rupture. Circ Res. 2000;86:101–108[Abstract/Free Full Text]
  41. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;2:941–944[CrossRef][Web of Science][Medline]
  42. Davies MJ, Woolf N, Rowles P, Richardson PD. Lipid and cellular constituents of unstable human aortic plaques. Basic Res Cardiol. 1994;89:33–39
  43. Galis ZS. Metalloproteases in remodeling of vascular extracellular matrix. Fibrin Proteol. 1999;13:54–63[CrossRef]
  44. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493–2503
  45. Van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36–44[Abstract/Free Full Text]
  46. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic. Circulation. 1995;92:1565–1569
  47. Diet F, Pratt R, Berry GJ, Momose N, Gibbons G, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94:2576–2767
  48. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensins II. Circulation. 1998;98:800–807[Abstract/Free Full Text]
  49. Ohishi M, Ueda M, Rakugi H, et al. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesion. J Hypertens. 1999;17:547–553[CrossRef][Web of Science][Medline]
  50. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372–1378[Abstract/Free Full Text]
  51. Hoshida S, Kato J, Nishino M, et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation. 2001;103(6):630–633[Abstract/Free Full Text]
  52. Schieffer B, Luchtefeld M, Hilfiker A, Drexler H. Activation of the JAK/STAT cascade by angiotensin II depends on the NAD(P)H oxidase. Circ Res. 2000;87:1195–1201[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schieffer, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schieffer, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?